NEXYRA
Advanced Research

Overview

Unlocking Omics | Powering precision

Disclaimer

This submission (including any information provided in writing or orally in connection with the same or any other query) is made on behalf of Nexyra Advanced Research, S.L. (the "Company", "we", "our" or "us").
This documentation is for information purposes only and is aimed exclusively at professional and institutional investors, as defined in Directive 2014/65/EU (MiFID II) and in current Spanish legislation on the securities market.
In no case does it constitute a public offer for sale, request for subscription or acquisition of securities, nor does it constitute investment recommendation or advice, in accordance with the provisions of Law 6/2023, of 17 March, on Securities Markets and Investment Services, or Regulation (EU) 2017/1129 of the European Parliament and of the Council.
No representations or warranties, express or implied, are made about the accuracy, completeness or timeliness of the information, estimates, projections or assumptions contained in this presentation. Neither the Company nor any of its directors, officers, employees, advisors or representatives assume any responsibility for such information or any investment decision that may be made based on it.

This presentation may contain forward-looking statements regarding our business, operations, financial condition, results and strategic plans. Such statements can be identified by expressions such as "anticipate", "believe", "estimate", "expect", "intend", "plan", "potential", "anticipate", "target" or other similar expressions.
Such statements are based on the Company's estimates, projections and expectations as of the date of the presentation and are subject to risks, uncertainties and factors beyond our control that could cause actual results to differ materially from those expressed or implied.
The forward-looking statements contained herein speak only as of the date of issuance. Nexyra Advanced Research, S.L. undertakes no obligation to update or revise such statements based on new information, future events or any other factors, except as required by applicable law.

01

Pioneers in the analysis of omics data

scientific curiosity

About us



Nexyra transforms the analysis of complex omics data into accessible and scalable solutions.

We integrate advanced bioinformatics, systems biology and artificial intelligence to accelerate the development of science from sample to interpretable data, providing validated knowledge, eliminating friction and making science more accessible.

Current clinical capabilities



PHENOTYPE

•Characterization of more than 18,000 clinical phenotypes.
•Enriched analysis using gene interaction networks and metabolic pathways.
•Improved clinical interpretation, classification by physiological system, integrating with real world evidence (RWE)

RARE DISEASES

•Integration of Orphanet and CRB for more than 7,000 rare diseases.
•Identification of expression and metabolism patterns under conditions of low prevalence (<5/10,000).
•Independent exploratory resource: specific and personalized queries.

From data to patient

DISEASESS

•Standardized multi-omics annotation: integration of gene and metabolomic data with clinical ontologies and curated bases.
•Broad coverage in more than 15,000 diseases in metabolic, neurological, endocrine, immune, cardiovascular and oncological systems.
•Multi-species compatibility: automatic mapping between human and murine genes.

TOXICOLOGY

•Analysis of detection of signatures associated with toxicity by drugs or chemical compounds.
• Clinical and regulatory applications: hepatotoxicity, neurotoxicity, oxidative stress, etc.
•Multi-source data: evidence from in vitro models, animal studies, and clinical observations.

About us

Democratization

Sequencing technologies and other high-performance platforms will continue to generate massive amounts of data.

Technology of the future

The report of the Polytechnic of Milano places Data Science and Omics Sciences among the health technologies of the future

Accelerate innovation in the development of advanced omics data analysis tools for drug discovery, precision medicine, and transformative biomedical research, ensuring that the right discoveries reach the right patients faster, safer, and smarter.

+80%

of data generated in precision medicine are not clinically integrated or interpreted vertically



Value creation elements

Innovative Strategy

At Nexyra, we focus our investments on the highest-value segments in computational biomedicine. Our value creation blocks are based on scientific and technological leadership, enabling our partners through next-generation bioinformatics platforms and applied science of excellence.

Preclinical Discovery and Development

From the identification of therapeutic targets to the personalized preclinical dossier.
Simplification of models and prioritization in segments of high clinical impact.
Automation, multi-omics analysis and computational industrialization with state-of-the-art platforms.

Leadership in enabling technologies

Monetization of proprietary assets and platforms, with a CAPEX-light, scalable and high-return model.

New ways of working

Operational excellence, strategic collaboration and focus on scientific and technological talent as a driver of sustainable growth.

VALUE BENCHMARK

In house vs Nexyra

Time to results
Up to 80% faster

Total cost of ownership
30 - 70% cost saving

Return to innovation
2 -3x faster ROI in publications, IP and competitive grants

Strategy in execution: simplifying our business model

STRATEGIC FOCUS

We prioritize higher-value biomedical segments (omics, AI, precision medicine).
We reduce complexity, concentrating on lines with high clinical impact and sustainable return.

TECHNOLOGICAL PLATFORM

Automation and scalability of multi-omics analysis using AI and advanced bioinformatics.

OPERATING MODEL

Evolution towards a CAPEX-light approach, more agile and efficient.
Simplifying internal processes with agile methodologies that accelerate execution.

Trading in highly attractive markets

01

Global R+D spending



Subcontracting fee



Global R+D spending grows by 3% between 2023 and 2030.

The trend of outsourcing continues.

5-7% CAGR (addressable CRO market growth 2024-2028)

>10% CAGR (addressable DDDDP market)

CRO

CRO specialized in bioinformatics, multi-omics analysis and applied artificial intelligence

02

Data-Driven Drug Discovery Partner

Technological-scientific partner that does not manufacture, but transforms biological data into actionable knowledge to accelerate the identification of targets, biomarkers and therapeutic candidates.

03

Omics & AI Discovery Enabler

Enabler of pharmaceutical innovation thanks to its expertise in omics sciences, machine learning and computational analysis.

Fuente: PhRMA membership survey; Statista; https://www.grandviewresearch.com/industry-analysis/drug-discovery-outsourcing-market; CRO/CDMO market analyst coverage; consultancy analysis

State-of-the-art technology that improves R+D profitability
Benefits of better prediction based on omics and clinical data

$7.7 *bn*

of spending by the top 20 pharmaceutical companies on clinical trials that ended in 2024

- Radical change is required to produce faster, safer, and better R+D results.
- Prediction, automation, and AI are key
- Nexyra Positions to Lead the Field



Key Factors for Superior Performance at Nexyra

Base market growth ("data-driven CRO"): 5–7%
(Turning point to monitor)
Advanced technology capability in data and AI (accelerating drug discovery and improving return)
Strategic partnership model (expanding the accessible market through collaborations)
Advantage in omics and bioinformatics (revealing hidden patterns in multimodal data)

With this factor, Nexyra is positioned to capture overall market growth with >10% over the long term







Our Business Model

Specific value proposition

•Strategic alliances with risk and benefit sharing, promoting high-impact projects.
•Integrated agreements that combine research, consulting and technological support services.
•Fee-for-service (FFS) for specific research or validation needs.



Nexyra: Better monetization of technology and assets

Improving operational efficiency by focusing on technology leadership and key competencies

	NEXYRA Today	Our vision for tomorrow
INTELLECTUAL PROPERTY	Validated Technology Leadership Intellectual Property Registration	Expanding leadership in key technology competencies in omics sciences
INNOVATION	Transcriptomics, metabolomics and multi-omics integration	Analysis service of all omics layers, ability to create digital twins and development of quantum computing.
POSITIONING	Data Analytics Partner	Opening a non-existent niche within the CRO market such as **Omics & AI Discovery Enabler**

Founding Team

Lucía González Llorente, PhD

CSO/CTO & Co-Founder

Senior researcher and PhD Laude in Molecular Biology from the University of Oviedo, with solid training in molecular biology, oncology, bioinformatics, biostatistics and clinical trials. With a degree in Biology (University of Oviedo), a Diploma in Advanced Studies (University of León) and a Master's degree in Bioinformatics and Biostatistics (UOC), she has developed a transversal career that connects basic science, data analysis and clinical applications.

His predoctoral stage focused on the identification of clinical biomarkers, and during his postdoctoral studies at the Severo Ochoa Center for Molecular Biology (CBM-UAM), he consolidated his specialization in bioinformatic analysis applied to omics and health data. With experience in leading institutions such as CBM-UAM and ISPA-FINBA, she has led translational analysis projects with an impact on public health and personalized medicine with more than 30 indexed articles (several as lead author) and a notable record of citations: her most influential publication exceeds 200 citations, a reflection of her impact on translational medicine.

Since 2021 she has been a Data Scientist at BIOW and actively collaborates with UCAM, integrating advanced analytics technologies into projects funded by competitive funds. He is a member of the Chair of Advanced Regenerative Medicine at UCAM, and collaborates as a benchmark in biomedical data science in its technological hub, positioning himself as a strategic profile for the design, evaluation and scaling of data-based solutions in clinical and pharmaceutical environments.

Miguel A. Andrés Gasco, Pre-Doc

CEO & Co-Founder

Leader in clinical research and biomedical development with extensive experience in complex care environments, especially in intensive care and cardiac surgery. Graduated in Nursing and Criminology (UCJC). Specialized in Extracorporeal Circulation and Perfusion (UAM), he has completed advanced training in reference centers such as the Hospital Clínico de Valencia, the Hospital La Paz and the ECMO team of Vall d'Hebron. He began his journey in research with experimental cardiac surgery programs at Idipaz.

He has worked as a Clinical Specialist for Zoll Medical Corporation, bringing expertise in advanced life support in civilian and military contexts.

Currently a PhD candidate in Biomedical Sciences (UCAM), he directs clinical research projects in precision medicine using atmospheric plasma and omics technologies from BIOW, in collaboration with UCAM HiTech, IISFJD, IIS-Getafe and collaborating with the Think tank Scienceforlife. He has made different indexed publications, it is worth highlighting his participation as co-author in a paper published in Biomedicines.

He has a solid background in clinical genetics, metabolomics (UCAM) and data science – carried out at IE University and IBM – as well as in leadership in VUCA environments through a Harvard Business School program. A member of the Chair of Advanced Regenerative Medicine and a speaker at international forums, he integrates scientific rigor, data analysis and strategic vision to turn biomedical research into high-impact solutions. He is currently pursuing an MBA and a Master's degree in Big Data & Business Intelligence at ENEB.

Advisory Board

Teresa Alarcos, PhD

Advisor & Chief Business Development Officer

Doctor of Medicine Laude from the University of Valladolid, she completed her training in management and leadership at Harvard Business School, as well as with scholarships at MIT and UCLA Anderson School of Management.

She has more than 20 years of management experience in multinationals in the pharmaceutical, telecommunications and internet sectors, and currently serves as an independent director in high-growth multinational technology companies.

Miguel A. Andrés Molinero, MBA.

Bachelor of Medicine, with training in management and leadership from IESE. He has more than 25 years of experience in the management of public hospitals in Madrid. He has served as Medical Director and Managing Director.

Specialist in hospital transformation based on Lean Healthcare. He developed the GHOS system together with Airbus, improving surgical efficiency and resource management.

Javier García Fernández

Team Leader at Sngular, Computer Engineer from the University of Oviedo, with more than 15 years of experience in the development of scalable applications in multidisciplinary environments.

His career combines technical leadership and strategic vision, contributing to the design and execution of robust and innovative solutions in highly demanding sectors.

5–7 % CAGR (2024–2028)

Expanding market

Differentiation

Omics Sciences, Artificial Intelligence and Advanced Bioinformatics

Impact projection

>10% growth

FUNDACIÓN Parque Científico de Madrid

EUIPO EUROPEAN UNION INTELLECTUAL PROPERTY OFFICE

REGISTRO TERRITORIAL DE LA PROPIEDAD INTELECTUAL COMUNIDAD DE MADRID

startup radar madrid

UCAM HiTech SPORT, FOOD & HEALTH INNOVATION HUB

Transfiere European Meeting on Science, Technology and Innovation

APTenisa Programa de ideación y aceleración de startups

Cofinanciado por:

GOBIERNO DE ESPAÑA MINISTERIO DE INDUSTRIA, COMERCIO Y TURISMO enisa

APTE Asociación de Parques Científicos y Tecnológicos de España

ParcBit Parc balear d'innovació tecnològica

Contact

www.nexyraresearch.com
connect@nexyraresearch.com
+34 646 017 495.

Our office

Parque científico de Madrid. C. Faraday, 7,
Fuencarral-El Pardo, 28049 Madrid.

Our office

Parque científico de Madrid. C. Faraday, 7,
Fuencarral-El Pardo, 28049 Madrid.

NEXYRA
Advanced Research

Unlocking Omics | Powering precision

@nexyraadvancedresearch

connect@nexyraresearch.com